



One two three four five six seven eight nine

### Hazard ratios

- Those eating little meat
  - Incidence rate (Cancer/CVD) =  $1713/151212 \times 100,000$   
=1133 per 100,000
- Those eating most meat
  - Incidence rate =  $2130/151315 \times 100,000$   
=1408 per 100,000
- Ratio of rates =  $1408/1133 = 1.25$
- Hazard is probability of event at set time point
- Hazard ratios can be interpreted as ratio of incidence rates.
- Probability of dying is 1.24 times higher in those eating most meat compared with those eating least
- Cox proportional hazards model

Barts and The London School of Medicine and Dentistry www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Session two concepts

- Types of data (e.g Numerical, categorical & sub-categories)
- Central tendency (mean, median, mode)
- Spread (Centiles, SD, variance)
- Graphs & plots (e.g. box, scatter, histograms)
- Probabilities
- Proportions
- Normal distribution
- Reference groups
- PICO(s)

Barts and The London School of Medicine and Dentistry www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Spread, central tendency, and normal distribution

Box and whisker plot of of weight of 100 boys

Histogram of weight of 1000 boys

Barts and The London School of Medicine and Dentistry

---

---

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Session three concepts

- Populations & Data sources (Birth & death registration, HES, GP data)
- Tables
- Standardisation
- Population pyramids

United Kingdom: 2010

India: 2010

Barts and The London School of Medicine and Dentistry

---

---

---

---

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Taking age into account

Direct standardisation  
Uses rates from population of interest and apply to standard population

Indirect standardisation  
Uses rates from reference population and calculates expected number of deaths

$7000 \times 0.3 / 1000 = 2.1$

**Figure 3b** Age-standardised death rates for all causes of death by deprivation twentieth, ages 15-64, 1999-2003

Age	Death rate/ 1000	Number in Standard population	Expected number of deaths
15-19	0.3	7000	2.1
20-24	0.5	7000	3.5
25-29	0.6	7000	4.2
30-34	0.8	7000	5.6
35-39	1.2	7000	8.4
40-44	1.7	7000	11.9
45-49	2.5	7000	17.5
50-54	3.9	7000	27.3
55-59	6.2	6000	37.2
60-64	9.7	5000	48.5

Barts and The London School of Medicine and Dentistry

---

---

---

---

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Session four concepts

- Proportions
- ARR, RR, OR
- 2x2 tables
- Confidence intervals
- P-values
- Chi-squared test
- Probability
- Inference
- Erikson framework
- (Sensitivity and specificity)

Barts and The London School of Medicine and Dentistry www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---

---

---


One two three four five six seven eight nine

### Confidence intervals and P-values

If 95% CI:

**95% probability that the interval spans the true population parameter**  
(assuming adequate internal validity)

P-value is the **probability of observing this value, or a more extreme value, if the null-hypothesis is true**  
(again assuming adequate internal validity)



www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---


One two three four five six seven eight nine

### 2x2, OR, RR, ARD

	Whooping cough	Not whooping cough	TOTALS
Immunised	55	104	159
Not immunised	9	4	13
TOTALS	64	108	172

Odds ratio = ratio of two odds  
 =  $(55/104) / (9/4)$   
 =  $(55 \times 4) / (9 \times 104)$   
 = 0.23 = odds of getting whooping cough if immunised compared to not being immunised

RR? ARD?



www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---


---

---

One two three four five six seven eight nine

### Session five concepts

- Probability
- Incidence
- Prevalence
- Sensitivity & specificity
- Positive predictive value
- Lead time and lead time bias
- Wilson Junger criteria



www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---

### Diagnosis using serology

Test says they do = 76%  
Sensitivity

People who really **do** have whooping cough

Test says they don't = 99%  
Specificity

People who really **don't** have whooping cough

---

---

---

---

---

---

---

---

### Two by two table

Likelihood of cancer if positive test = positive predictive value =  $180000/3510000=5\%$

	Breast cancer	Not breast cancer	TOTALS
Positive test	180,000	3,330,000	3,510,000
Negative test	20,000	29,970,000	29,990,000
TOTALS	200,000	33,300,000	33,500,000

Likelihood of not having cancer if negative test = negative predictive value =  $29970000/29990000=99.9\%$

---

---

---

---

---

---

---

---

### Positive and negative predictive value

If I have a positive test what is the likelihood that I have breast cancer? Positive predictive value =  $1/20 = 5\%$

If I have a negative test what is the likelihood that I don't have breast cancer? Negative predictive value is over  $99/100 = 99\%$

---

---

---

---

---

---

---

---

### Should we screen?

- Screening detects disease earlier
- How do you measure increase in life expectancy?



- **Lead time** is the length of time between the detection of a disease (usually based on new, experimental criteria) and its usual clinical presentation and diagnosis (based on traditional criteria)
- **Lead time bias** is the bias arising in survival analyses when the disease is detected earlier in one group than the other

---

---

---

---

---

---

---

---

### Wilson and Jungner criteria (WHO 1968)

1. The condition should be an important health problem.
2. There should be a treatment for the condition.
3. Facilities for diagnosis and treatment should be available.
4. There should be a latent stage of the disease.
5. There should be a test or examination for the condition.
6. The test should be acceptable to the population.
7. The natural history of the disease should be adequately understood.
8. There should be an agreed policy on whom to treat.
9. The total cost of finding a case should be economically balanced in relation to medical expenditure as a whole.
10. Case-finding should be a continuous process, not just a "once and for all" project.

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

#### Session six concepts

- Study types
- Incidence
- Odds ratios
- Chi-squared test
- Cohort study
- Case-control study

---

---

---

---

---

---

---

---

Ecological studies

- Look at correlations between exposure and outcome
  - Geographical (within or between countries)
  - Over time
- Collect published data/routine statistics on:
  - Risk factors eg national food consumption data
  - Disease eg mortality rates, published survey data
- Compare characteristics of *populations* (not individuals)

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---


---

---

---

---





---

---

---

---

---

---

---

---

One two three four five six seven eight nine

**Session seven concepts**

- Cohort and historical cohort studies
- Types of data (numerical, categorical)
- Confidence intervals
- P-values and statistical significance
- Clinical importance
- Chi-squared test
- Relative risk (and comparison to ORs)
- Trials
- Confounding
- Coding
- Bradford Hill criteria

Barts and The London  
School of Medicine and Dentistry

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

Can we believe our results?  
First we need to consider:

- *Chance*
- *Bias*
- *Confounding*

⇒ Is it causal?

---

---

---

---


---

---

---

---

Random error



---

---

---

---


---

---

---

---

Bias



---

---

---

---

---

---

---

---

### Causal inference in observational studies

- Bradford Hill “criteria”
  - Size of effect
  - Dose response
  - Consistency
  - Biological plausibility
  - Temporality

---

---

---

---

---

---

---

---

### Bradford Hill (1965)

- **Temporality**
- **Strength**
- **Dose-response relationship (trend)**
- **Reversibility**
- Biological plausibility
- Consistency
- Specificity
- Analogy
- Coherence

(Proc R Soc Med 1965; 58: 295-300)

---

---

---

---

---

---

---

---

One two three four five six seven eight nine

### Session eight concepts

- Hierarchy of evidence
- Trials
- Randomisation
- Blinding
- Confidence intervals
- Statistical significance
- P-values
- Chi-squared test
- Logistic regression
- Confounding
- ITT & Per protocol
- Clinical importance vs statistical significance
- Ethics

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---


---

---

One two three four five six seven eight nine

**Session nine concepts**

- PICO(s)
- Systematic review
- Meta analysis
- Forest plots
- Odds ratios
- Relative risk
- Confidence intervals
- Statistical significance
- P-values
- Confounding
- Descriptive statistics
- Risk difference
- NNT
- t-test
- Regression

 Barts and The London  
School of Medicine and Dentistry [www.smd.qmul.ac.uk](http://www.smd.qmul.ac.uk)

---

---

---

---

---

---

---

---

---

---

---

---


**Describing the Research Question: PICO**

**P Population**      Where and how are participants recruited?  
What are the inclusion and exclusion criteria?

**I Intervention**      What is the active intervention? It should be  
described in enough detail to allow another  
researcher to replicate it

**C Comparison**      What is the control? This might be an established  
treatment or 'routine care', or else a placebo,  
sham, or inactive control

**O Outcome**      How and when will outcome be assessed?

 Barts and The London  
School of Medicine and Dentistry [www.smd.qmul.ac.uk](http://www.smd.qmul.ac.uk)

---

---

---

---

---

---

---

---

---


---

---

---

**Systematic reviews**

- Develop research question
- Scoping
- Refine research question
- Search abstracts ->reject/accept
- Search full-texts -> reject/accept
- Abstract data (independent – team up)
- Analyse (e.g. meta-analysis, or descriptive)
- Write-up dissertation
- Publish results

 Barts and The London  
School of Medicine and Dentistry [www.smd.qmul.ac.uk](http://www.smd.qmul.ac.uk)

---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

---

---

### Difference between proportions

Does tamiflu (oseltamivir) prevent respiratory tract infections requiring antibiotics in children with confirmed influenza

28% in those given placebo  
17% in those given tamiflu  
Difference 11 (4 to 19)

www.smd.qmul.ac.uk

---

---

---

---

---

---

---

---

---

---

---

---

### Number needed to treat

Number of people you need to treat to avoid one adverse event

$$\text{NNT} = 1/\text{Risk difference}$$

For tamiflu

Risk difference = 0.11

Number needed to treat =  $1/0.11=9$

95% confidence interval (5 to 29)

---

---

---

---

---

---

---

---

### Continuous outcomes

Mean duration of symptoms

One study by Vrese

Control mean(SD) = 8.9 (1.0) days

Probiotics mean(SD) = 7.0 (0.5) days

Difference = 1.9

95% confidence interval 1.75 to 2.05;  $P < 0.05$

---

---

---

---

---

---

---

---

### Continuous outcomes

Simple comparison of two groups

Use a t-test

Gives confidence interval for difference

Adjusting for confounders

Use regression model

Present results as "adjusted difference"

---

---

---

---

---

---

---

---